NEW ZEALAND GAZETTE

No. 158

Product:
Atrovent

Active Ingredient:
Ipratropium bromide monohydrate 0.021mg/dose equivalent to 0.020mg/dose ipratropium bromide anhydrous

Dosage Form:
Aerosol inhaler, metered dose

New Zealand Sponsor:
Boehringer Ingelheim (NZ) Limited

Manufacturer:
Boehringer Ingelheim Pharma KG, Ingelheim am Rhein, Germany

Product:
Cipralex

Active Ingredient:
Escitalopram oxalate 12.77mg equivalent to 10mg escitalopram

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Zuellig-Pharma Limited

Manufacturer:
H Lundbeck A/S, Copenhagen-Valby, Copenhagen, Denmark

Product:
Cipralex

Active Ingredient:
Escitalopram oxalate 19.16mg equivalent to 15mg escitalopram

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Zuellig-Pharma Limited

Manufacturer:
H Lundbeck A/S, Copenhagen-Valby, Copenhagen, Denmark

Product:
Cipralex

Active Ingredient:
Escitalopram oxalate 25.54mg equivalent to 20mg escitalopram

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Zuellig-Pharma Limited

Manufacturer:
H Lundbeck A/S, Copenhagen-Valby, Copenhagen, Denmark

Product:
Cipralex

Active Ingredient:
Escitalopram oxalate 6.39mg equivalent to 5mg escitalopram

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Zuellig-Pharma Limited

Manufacturer:
H Lundbeck A/S, Copenhagen-Valby, Copenhagen, Denmark

Product:
Somac

Active Ingredient:
Pantoprazole sodium 42.3mg equivalent to 40mg pantoprazole

Dosage Form:
Powder for injection

New Zealand Sponsor:
Pharmacia Limited Company trading as Pharmacia

Manufacturer:
Dr Rentschler Biotechnologie GmbH & Co KG, Laupheim, Germany
Wasserburger Arzneimittelwerk Dr Madaus GmbH, Wasserburg, Germany

Dated this 22nd day of October 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go7209

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the schedule hereto:

Schedule

Product:
Daivonex

Active Ingredient:
Calcipotriol 50µg/g

Dosage Form:
Topical ointment

New Zealand Sponsor:
CSL (New Zealand) Limited

Manufacturer:
Leo Laboratories Limited, Crumlin, Dublin, Eire

Dated this 22nd day of October 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go7210

New Zealand Public Health and Disability Act 2000

Direction to Waikato District Health Board—Use of DHB Facilities For Filming or Recording

In light of controversy recorded in the judgment of Hon Justice Heath in Re an unborn child (HC Hamilton, 11 October 2002) concerning a woman’s attempt to have the birth of her child recorded for purposes that have been acknowledged as including a pornographic film, I regard it as inconsistent with the objectives of a DHB that its facilities be used for any such purpose.

It is the policy of the Government that the resources of DHBs are to be applied in pursuance of their objectives, and in particular, that the facilities of DHBs are not to be used to produce or promote pornography.

Therefore, pursuant to section 32 of the New Zealand Public Health and Disability Act 2000, I direct the Waikato DHB as follows: